Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Blood (2024) 143 (2): 152–165.

https://doi.org/10.1182/blood.2023021348

Published: 2024

Includes: Supplemental data

Journal Articles

Patient, Caregiver, and Healthcare Provider Priorities for Future Multiple Myeloma Research: Results of a James Lind Alliance Priority Setting Partnership

Anthony Reiman, Samantha Fowler, Lauren McLaughlin, Sarah Bridges, Marc Robichaud, Barbara Ridgway, Donna E. Reece, Kevin W Song, Lorelei Dalrymple, Robin Sully, Sharon Nason, Suzanne Rowland, Trish MacDonald, William Paine

Blood (2021) 138 (Supplement 1): 4984.

https://doi.org/10.1182/blood-2021-145096

Published: 2021

Journal Articles

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Hira S Mian, Richard Leblanc, Martha L Louzada, Esther Masih-Khan, Arleigh McCurdy, Christopher P. Venner, Julie Stakiw, Moustafa Kardjadj, Victor H Jimenez-Zepeda, Michael Sebag, Darrell J White, Muhammad Aslam, Kevin W Song, Anthony Reiman, Rami Kotb, Engin Gul, Donna E. Reece

Blood (2021) 138 (Supplement 1): 4721.

https://doi.org/10.1182/blood-2021-148191

Published: 2021

Journal Articles

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Hira S Mian, MD, Christine Eisfeld, Christopher P. Venner, MD, Victor Jimenez-Zepeda, MD, Cyrus Khandanpour, MD, Arleigh McCurdy, MD BSc, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Richard Leblanc, MD FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Darrell J White, MD, Julie Stakiw, MD, Anthony Reiman, MD, Martha L Louzada, MDMSc, Muhammad Aslam, MD, Rami Kotb, MD, Engin Gul, BS, MBA, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-133372

Published: 2020

Journal Articles

Characteristics and Treatment Outcomes of Plasmablastic Lymphoma in British Columbia (BC)

Nicole Chien, MBBChir, Diego Villa, MDMPH, Ciara L. Freeman, MSc, MBBChir, Graham W. Slack, MD, Kerry J. Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Laurie H. Sehn, MDMPH, Kevin W Song, MD FRCPC, Alina S. Gerrie, MD MPH

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142351

Published: 2020

Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134189

Published: 2020

Journal Articles

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, MD BSc, Christopher P. Venner, MD, Martha L Louzada, MDMSc, Richard LeBlanc, MD FRCPC, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Victor Jimenez-Zepeda, MD, Rami Kotb, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Hira S Mian, MD, Darrell J White, MD, Julie Stakiw, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-142800

Published: 2020

Journal Articles

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Erica Tsang, Diego Villa, MD, Federica Loscocco, Alina S Gerrie, MD, Giuseppe Visani, Maryse Power, MB, Barbara Guiducci, Cristina Clissa, MD PhD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc, Kevin W Song, MD, Cindy Toze, Yasser Abou-Mourad, Heather Sutherland, MD, David Sanford, MD, Stephen H Nantel, MD, Laurie H. Sehn, MDMPH, David W. Scott, MD PhD FRACP, FRCPA, Alessandro Isidori, MD PhD

Blood (2017) 130 (Supplement 1): 3291.

https://doi.org/10.1182/blood.V130.Suppl_1.3291.3291

Published: 2017

Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Blood (2017) 130 (Supplement 1): 1888.

https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888

Published: 2017

Journal Articles

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Wasithep Limvorapitak, MD, Michael J Barnett, BM, Donna Hogge, Donna L Forrest, MD, Thomas J Nevill, MD, Sujaatha Narayanan, MBBS, Maryse Power, MB, Stephen H Nantel, MD, Raewyn Broady, MBChB, FRACP, Kevin W Song, MD, Cynthia L Toze, MD, Yasser Abou Mourad, MD, Heather Sutherland, MD, Alina S Gerrie, MD, Jennifer White, MD, David Sanford, MD

Blood (2017) 130 (Supplement 1): 4544.

https://doi.org/10.1182/blood.V130.Suppl_1.4544.4544

Published: 2017

Journal Articles

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Neha Mehta-Shah, MD, Stephanie Teja, Yu Tao, MD, Amanda F. Cashen, MD, Anne Beaven, MD, Onder Alpdogan, MD, Pierluigi Porcu, MD, Mackenzie Wiggin, Kevin W Song, MD, Musa Alzahrani, Parastoo B. Dahi, MD, Alison J. Moskowitz, MD, Steven M. Horwitz, MD, Eric D. Jacobsen, MD

Blood (2017) 130 (Supplement 1): 4597.

https://doi.org/10.1182/blood.V130.Suppl_1.4597.4597

Published: 2017

Journal Articles

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Blood (2017) 130 (Supplement 1): 1811.

https://doi.org/10.1182/blood.V130.Suppl_1.1811.1811

Published: 2017

Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1812.

https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812

Published: 2017

Journal Articles

Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide

Amir Siddiqui, Donna E. Hogge, MD PhD, Thomas J. Nevill, MD, Stephen H. Nantel, MD FRCPC, Michael J Barnett, BMBS, Raewyn Broady, MBChB, Donna L. Forrest, MD, Sujaatha Narayanan, MBBS, MRCP, FRCPath, Maryse M Power, MD, Kevin W. Song, MD, Cynthia L. Toze, MD MHSc, FRCPC, Yasser Abou Mourad, MD, Heather J. Sutherland, MD PhD, Alina S. Gerrie, MD MPH, FRCPC, David Sanford, MD FRCPC

Blood (2016) 128 (22): 2814.

https://doi.org/10.1182/blood.V128.22.2814.2814

Published: 2016

Journal Articles

Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada

Katie Y. Zhu, BHSc, Kevin W. Song, MD, Joseph M Connors, MD, Tracy Tucker, PhD FCCMG, Graham W. Slack, MD, Yasser Abou Mourad, MD, Michael J Barnett, BMBS, FRCPC, FRCP, FRCPath, Donna L. Forrest, MD FRCPC, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD FRCPC, Sujaatha Narayanan, MBBS, MRCP, FRCPath, Thomas J. Nevill, MD FRCPC, Maryse M Power, MB, MRCPI, FRCPath, David Sanford, MD FRCPC, Cynthia L. Toze, MD MHSc, FRCPC, Heather J. Sutherland, MD PhD FRCPC, Laurie H. Sehn, Raewyn Broady, MBChB, FRACP, Alina S. Gerrie, MD MPH, FRCPC

Blood (2016) 128 (22): 1113.

https://doi.org/10.1182/blood.V128.22.1113.1113

Published: 2016

Journal Articles

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed AL Amyloidosis: Experience of Two Centers in Canada

Hatem Alahwal, MPH, MBBS, Kevin W. Song, MD, Peter Duggan, MD, Heather J. Sutherland, MD PhD, Paola Neri, MD PhD, Raewyn Broady, MBChB, Nizar J. Bahlis, MD, Victor Jimenez-Zepeda, MD

Blood (2016) 128 (22): 2131.

https://doi.org/10.1182/blood.V128.22.2131.2131

Published: 2016

Journal Articles

Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia

Blood (2016) 128 (22): 5852.

https://doi.org/10.1182/blood.V128.22.5852.5852

Published: 2016

Journal Articles

Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety

David S. Siegel, MD PhD, Gary J. Schiller, MD, Kevin W. Song, MD, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Fred J. Reu, Ehsan Malek, MD, Jorge L Mouro, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Syed Rizvi, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 4497.

https://doi.org/10.1182/blood.V128.22.4497.4497

Published: 2016

Journal Articles

Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes

Musa Alzahrani, MBBS, ABIM, Maryse M Power, MD, Emilie Nevill, Yasser Abou Mourad, MD, Michael J Barnett, BMBS, Raewyn Broady, MBChB, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, FRCPC, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD FRCPC, David Sanford, MD FRCPC, Heather J. Sutherland, MD PhD FRCPC, Cynthia L. Toze, MD MHSc, FRCPC, Kevin W. Song, MD, Kevin W. Song, MD, Thomas J. Nevill, MD FRCPC, Sujaatha Narayanan

Blood (2016) 128 (22): 4662.

https://doi.org/10.1182/blood.V128.22.4662.4662

Published: 2016

Journal Articles

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin W. Song, MD, Jean Roy, MD, Martha L Louzada, MD, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul, BSc

Blood (2016) 128 (22): 4632.

https://doi.org/10.1182/blood.V128.22.4632.4632

Published: 2016

NARROW

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Patient, Caregiver, and Healthcare Provider Priorities for Future Multiple Myeloma Research: Results of a James Lind Alliance Priority Setting Partnership

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Characteristics and Treatment Outcomes of Plasmablastic Lymphoma in British Columbia (BC)

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide

Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed AL Amyloidosis: Experience of Two Centers in Canada

Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia

Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety

Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only